Antimalarial drug response of Plasmodium falciparum from Zaria, Nigeria

Trans R Soc Trop Med Hyg. 1995 Jul-Aug;89(4):422-5. doi: 10.1016/0035-9203(95)90037-3.

Abstract

The sensitivity of Zaria strains of Plasmodium falciparum to chloroquine, mefloquine, quinine and sulphadoxine/pyrimethamine was investigated 5 years after the appearance of in vivo/in vitro chloroquine resistance in urban Zaria. Infections in 36/43 children (83.7%) treated with chloroquine were sensitive while those in 7 (16.3%) were resistant. 8/13 isolates cultured (61.5%) were sensitive in vitro to chloroquine and 5 (38.5%) were resistant. Of the cultured isolates, 13/13 (100%), 12/13 (92.3%) and 5/7 (71.4%) showed mefloquine, quinine and sulphadoxine/pyrimethamine sensitivity, respectively. The results confirmed chloroquine and sulphadoxine/pyrimethamine resistance in urban Zaria and revealed emerging quinine resistance. Resistance to chloroquine and sulphadoxine/pyrimethamine is at RI level and chloroquine should continue to be the first-line drug for the treatment and prevention of P. falciparum infection in the Zaria area of northern Nigeria. We suggest that, while quinine serves as second-line drug, mefloquine should be reserved for infections resistant to chloroquine, quinine and sulphadoxine/pyrimethamine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimalarials / therapeutic use*
  • Child
  • Child, Preschool
  • Chloroquine / therapeutic use*
  • Drug Combinations
  • Drug Resistance
  • Humans
  • Infant
  • Malaria, Falciparum / drug therapy*
  • Mefloquine / therapeutic use
  • Nigeria
  • Parasitemia / drug therapy*
  • Plasmodium falciparum / drug effects*
  • Pyrimethamine / therapeutic use
  • Quinine / therapeutic use
  • Sulfadoxine / therapeutic use

Substances

  • Antimalarials
  • Drug Combinations
  • Sulfadoxine
  • Chloroquine
  • Quinine
  • Mefloquine
  • Pyrimethamine